TY - JOUR
T1 - Effect of Lactobacillus reuteri on Cell Viability and PGE2 Production in Human Gingival Fibroblasts
AU - Castiblanco, Gina A.
AU - Yucel-Lindberg, Tulay
AU - Roos, Stefan
AU - Twetman, Svante
N1 - The original version of this article unfortunately contained mistakes and the authors are hereby publishing this erratum.
The author realized that the ID number of one probiotic strain was typed incorrectly. The strain “ATCC PTA 5298” should be captured as “ATCC PTA 5289”. It was captured five times throughout the manuscript and these have been corrected in the original article.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Emerging evidence suggests that probiotic therapy can play a role in the prevention and management of oral inflammatory diseases through immunomodulation and down-regulation of the inflammatory cascade. The aim of this in vitro study was to investigate the viability of human gingival fibroblasts (HGF) and its production of prostaglandin E2 (PGE2), when exposed to supernatants of two mixed Lactobacillus reuteri strains (ATCC PTA 5289 and DSM 17938). The experiments were conducted in the presence and absence of the pro-inflammatory cytokine IL-1β. L. reuteri strains were grown and the bacterial supernatant was collected. The cell-free supernatant was diluted to concentrations equivalent to the ones produced by 0.5 to 5.0 × 10(7) CFU/mL bacteria. Cell viability was assessed with the MTT colorimetric assay and the amount of PGE2 in the cell culture medium was determined using the monoclonal enzyme immune assay kits. Our findings showed that none of the L. reuteri supernatants were cytotoxic or affected the viability of HGF. The most concentrated bacterial supernatant stimulated the production of PGE2 by the gingival cells in a significant way in the presence of IL-1β (p < 0.05), suggesting that bacterial products secreted from L. reuteri might play a role in the resolution of inflammation in HGF. Thus, our findings justify further investigations on the influence of probiotic bacteria on gingival inflammatory reactions.
AB - Emerging evidence suggests that probiotic therapy can play a role in the prevention and management of oral inflammatory diseases through immunomodulation and down-regulation of the inflammatory cascade. The aim of this in vitro study was to investigate the viability of human gingival fibroblasts (HGF) and its production of prostaglandin E2 (PGE2), when exposed to supernatants of two mixed Lactobacillus reuteri strains (ATCC PTA 5289 and DSM 17938). The experiments were conducted in the presence and absence of the pro-inflammatory cytokine IL-1β. L. reuteri strains were grown and the bacterial supernatant was collected. The cell-free supernatant was diluted to concentrations equivalent to the ones produced by 0.5 to 5.0 × 10(7) CFU/mL bacteria. Cell viability was assessed with the MTT colorimetric assay and the amount of PGE2 in the cell culture medium was determined using the monoclonal enzyme immune assay kits. Our findings showed that none of the L. reuteri supernatants were cytotoxic or affected the viability of HGF. The most concentrated bacterial supernatant stimulated the production of PGE2 by the gingival cells in a significant way in the presence of IL-1β (p < 0.05), suggesting that bacterial products secreted from L. reuteri might play a role in the resolution of inflammation in HGF. Thus, our findings justify further investigations on the influence of probiotic bacteria on gingival inflammatory reactions.
UR - https://link.springer.com/article/10.1007%2Fs12602-017-9254-1
U2 - 10.1007/s12602-016-9246-6
DO - 10.1007/s12602-016-9246-6
M3 - Journal article
C2 - 28028690
SN - 1867-1306
VL - 9
SP - 278
EP - 283
JO - Probiotics and Antimicrobial Proteins
JF - Probiotics and Antimicrobial Proteins
IS - 3
ER -
